Cyfuse Biomedical KK (TSE:4892) ROCE %: 0.00% (As of Dec. 2025)


TSE:4892 Cyfuse Biomedical KK TSE:4892
53 GF Score
Price 円552.00
GF Value 円2,179.63
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK ROCE %?

Cyfuse Biomedical KK TSE:4892 +2.99% 53 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4892 with a GF Score™ of 53/100 and a GF Value™ of 円2,179.63 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cyfuse Biomedical KK's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Cyfuse Biomedical KK  (TSE:4892) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cyfuse Biomedical KK ROCE % Related Terms

Cyfuse Biomedical KK ROCE % Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK ROCE % Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 7.07 -13.89 -15.01 -26.81 -23.83

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.85 -35.23 0.00 0.00 -26.17
TSE:4892
53GF Score
Cyfuse Biomedical KK TSE:4892
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK ROCE % Calculation

Cyfuse Biomedical KK's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-747.022/( ( (3518.001 - 648.595) + (4266.026 - 866.063) )/ 2 )
=-747.022/( (2869.406+3399.963)/ 2 )
=-747.022/3134.6845
=-23.83 %

Cyfuse Biomedical KK's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=0/( ( (4299.728 - 670.75) + (4266.026 - 866.063) )/ 2 )
=0/( ( 3628.978 + 3399.963 )/ 2 )
=0/3514.4705
=0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Cyfuse Biomedical KK (TSE:4892) has a ROCE % of 0.00% as of Dec. 2025.
Is Cyfuse Biomedical KK's ROCE % too high?
Cyfuse Biomedical KK's current ROCE % is 0.00%. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's ROCE % compare to ZTS and UTHR?
Cyfuse Biomedical KK's ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,179.63, compared to a current price of 円552.00 — trading 74.7% below its estimated fair value. The current ROCE % is 0.00%. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円552.00 is trading 74.7% below its estimated GF Value™ of 円2,179.63. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for TSE:4892:

  • ROCE %: 0.00%
  • GF Value™: 円2,179.63 vs. price of 円552.00 (74.7% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score

Get the complete analysis for TSE:4892

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円552.00
Price
円2,179.63
GF Value